BG64554B1 - 4-фенил-пиридинови производни, метод за получаването им и тяхното използване - Google Patents
4-фенил-пиридинови производни, метод за получаването им и тяхното използване Download PDFInfo
- Publication number
- BG64554B1 BG64554B1 BG104187A BG10418700A BG64554B1 BG 64554 B1 BG64554 B1 BG 64554B1 BG 104187 A BG104187 A BG 104187A BG 10418700 A BG10418700 A BG 10418700A BG 64554 B1 BG64554 B1 BG 64554B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- methyl
- tolyl
- bis
- mmol
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99103504 | 1999-02-24 | ||
EP99123689 | 1999-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
BG104187A BG104187A (en) | 2000-11-30 |
BG64554B1 true BG64554B1 (bg) | 2005-07-29 |
Family
ID=26152908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG104187A BG64554B1 (bg) | 1999-02-24 | 2000-02-24 | 4-фенил-пиридинови производни, метод за получаването им и тяхното използване |
Country Status (55)
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058640A2 (en) * | 1998-05-11 | 1999-11-18 | Philadelphia Health And Education Corporation | Mct-1, a human oncogene |
PL350427A1 (en) | 1999-02-24 | 2002-12-16 | Hoffmann La Roche | Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists |
US6291465B1 (en) * | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
DK1103545T3 (da) * | 1999-11-29 | 2004-03-15 | Hoffmann La Roche | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
JP3938651B2 (ja) * | 2000-04-13 | 2007-06-27 | セントラル硝子株式会社 | 光学活性α−メチル−ビス−3、5−(トリフルオロメチル)ベンジルアミンの製造方法 |
DK1303490T3 (da) * | 2000-07-14 | 2008-08-25 | Hoffmann La Roche | N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater |
TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
EP1349541B1 (en) * | 2000-12-14 | 2006-10-04 | F. Hoffman-la Roche AG | Self emulsifying lipid matrix (selm) |
US6531597B2 (en) * | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
DE60220997T2 (de) * | 2001-03-27 | 2008-03-13 | Eisai R&D Management Co., Ltd. | N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält |
BR0209151A (pt) * | 2001-04-23 | 2004-07-13 | Hoffmann La Roche | Uso de antagonistas de receptor nk-1 contra hiperplasia prostática benigna |
PT2266558T (pt) * | 2001-06-07 | 2017-07-21 | Analgesic Neuropharmaceuticals Llc | Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
AU2002340847B2 (en) * | 2001-09-10 | 2007-09-13 | F. Hoffmann-La Roche Ag | Oily thixotropic formulations |
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
EP1542967A1 (en) | 2002-09-20 | 2005-06-22 | Pfizer Products Inc. | Amide and sulfonamide ligands for the estrogen receptor |
AU2003298034B2 (en) | 2002-12-06 | 2011-04-21 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
CA2514037C (en) * | 2003-01-31 | 2012-03-13 | F. Hoffmann-La Roche Ag | Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide |
BRPI0412291A (pt) * | 2003-07-03 | 2006-09-19 | Hoffmann La Roche | antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia |
US7288658B2 (en) * | 2003-07-15 | 2007-10-30 | Hoffmann-La Roche Inc. | Process for preparation of pyridine derivatives |
ES2375134T3 (es) | 2003-07-30 | 2012-02-27 | Xenon Pharmaceuticals Inc. | Derivados de piperazina y su uso como agentes terapéuticos. |
ES2380020T3 (es) * | 2004-07-06 | 2012-05-07 | Xenon Pharmaceuticals Inc. | Derivados de nicotinamida y su uso como agentes terapéuticos |
MX2007000198A (es) | 2004-07-06 | 2007-03-15 | Hoffmann La Roche | Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1. |
KR100881240B1 (ko) * | 2004-07-06 | 2009-02-05 | 에프. 호프만-라 로슈 아게 | Nk-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법 |
US20060030556A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency |
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
JP5094398B2 (ja) | 2004-09-20 | 2012-12-12 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環式誘導体およびステアロイル−CoAデサチュラーゼのメディエータとしてのそれらの使用 |
EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
WO2006060174A1 (en) * | 2004-11-15 | 2006-06-08 | Honeywell International Inc. | Isocyanate-based polymer foams with nano-scale materials |
BRPI0606843A2 (pt) * | 2005-02-22 | 2009-07-21 | Hoffmann La Roche | antagonistas de nk 1 |
WO2006091800A2 (en) * | 2005-02-24 | 2006-08-31 | Janssen Pharmaceutica N.V. | Novel pyridine derivatives as potassium ion channel openers |
WO2006089674A2 (en) | 2005-02-25 | 2006-08-31 | F.Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
MX2007011489A (es) * | 2005-03-23 | 2007-10-11 | Hoffmann La Roche | Metabolitos para antagonistas del receptor neurokinina 1 (nk-1) para emesis. |
CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
WO2007021982A2 (en) * | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
SI1928886T1 (sl) | 2005-09-09 | 2011-08-31 | Glaxosmithkline Llc | Derivati piridina in njihova uporaba pri zdravljenju psihotiäśnih motenj |
CN103893145A (zh) | 2005-09-23 | 2014-07-02 | 弗·哈夫曼-拉罗切有限公司 | 新型制剂 |
EP1945632B1 (en) * | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7872022B2 (en) | 2006-04-03 | 2011-01-18 | Hoffmann-La Roche Inc. | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
ES2554353T3 (es) | 2006-04-07 | 2015-12-18 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
RS55360B1 (sr) | 2007-12-07 | 2017-03-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina |
WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
MX2012002369A (es) * | 2009-08-27 | 2012-03-29 | Glaxosmithkline Llc | Formas de anhidrato de un derivado de piridina. |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
MY159393A (en) | 2009-11-18 | 2016-12-30 | Helsinn Healthcare Sa | Compositions for treating centrally mediated nausea and vomiting |
TW201143768A (en) * | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
ES2579965T3 (es) | 2010-04-07 | 2016-08-17 | Vertex Pharmaceuticals Incorporated | Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico |
BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
EP2560488B1 (en) * | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
US20140155419A1 (en) * | 2011-07-29 | 2014-06-05 | Erkan Baloglu | Compounds and methods |
US20140256740A1 (en) * | 2011-07-29 | 2014-09-11 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
PL2744497T3 (pl) | 2011-10-18 | 2016-10-31 | Terapeutyczne połączenia netupitantu i palonosetronu | |
CA2852991C (en) | 2011-11-08 | 2019-12-31 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
JP5806420B1 (ja) * | 2013-11-08 | 2015-11-10 | キッセイ薬品工業株式会社 | カルボキシメチルピペリジン誘導体 |
PT3068392T (pt) | 2013-11-12 | 2021-05-14 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr) |
DK3424534T3 (da) | 2014-04-15 | 2021-07-26 | Vertex Pharma | Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator |
EP3140007A1 (en) * | 2014-05-05 | 2017-03-15 | Apicore US LLC | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) * | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
TW201613888A (en) | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
BR112017010406B1 (pt) | 2014-11-18 | 2021-03-09 | Vertex Pharmaceuticals Incorporated | processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência |
KR20170122777A (ko) | 2015-03-04 | 2017-11-06 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피턴트에 의한 치료 방법 |
CN105061303A (zh) * | 2015-08-03 | 2015-11-18 | 成都欣捷高新技术开发有限公司 | 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法 |
EP4019018A1 (en) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
ES2813596T3 (es) | 2015-12-07 | 2021-03-24 | Kissei Pharmaceutical | Antagonista del receptor NK1 |
TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
CN106892864A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种奈妥皮坦游离碱的晶型a及其制备方法 |
EA201891472A1 (ru) * | 2015-12-22 | 2018-12-28 | Такеда Фармасьютикал Компани Лимитед | Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком |
CA3059418A1 (en) | 2017-04-10 | 2018-10-18 | Chase Therapeutics Corporation | Nk1-antagonist combination and method for treating synucleinopathies |
US11266633B2 (en) | 2017-06-30 | 2022-03-08 | Chase Therapeutics Corporation | NK-1 antagonist compositions and methods for use in treating depression |
CN109384712B (zh) * | 2017-08-14 | 2021-05-07 | 北京宽厚医药科技有限公司 | 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用 |
WO2019038656A1 (en) | 2017-08-21 | 2019-02-28 | Leiutis Pharmaceuticals Pvt, Ltd | NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY |
BR112020015484A2 (pt) * | 2018-09-28 | 2021-04-27 | Vanda Pharmaceuticals Inc. | métodos para tratamento de um sujeito prestes a se envolver em uma atividade que implica em movimento indutor de enjoo e de um sujeito com enjoo de movimento ou pelo menos um sintoma de enjoo de movimento, composto, e, composição farmacêutica |
US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
EP3902793A4 (en) * | 2018-12-24 | 2022-09-07 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | MANUFACTURE OF A CHEMICAL COMPOUND, NEW FORM OF SALT, AND ASSOCIATED THERAPEUTIC USES |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
US20230190740A1 (en) | 2020-04-03 | 2023-06-22 | Nerre Therapeutics Limited | An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods) |
CN115697332A (zh) | 2020-06-02 | 2023-02-03 | 尼尔医疗有限公司 | 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂 |
WO2024126398A1 (en) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Fixed dose combination comprising netupitant and palonosetron |
EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
WO2024126408A1 (en) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1557420A (en) | 1977-03-10 | 1979-12-12 | Soc D Etudes Prod Chimique | Preparation of isobutyramide derivatives |
KR810001320B1 (ko) | 1977-03-17 | 1981-10-14 | 삐에르 위브 | 신규한 이소부티라미드류의 제조방법 |
KR810001697B1 (ko) | 1978-02-06 | 1981-10-27 | 삐에르 위브 | 이소부티라미드 유도체의 신규한 제조방법 |
DE3366369D1 (en) | 1982-03-17 | 1986-10-30 | Smith Kline French Lab | Pyridine derivatives |
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
GB8607313D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
US4994456A (en) | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
HU207047B (en) | 1989-11-07 | 1993-03-01 | Richter Gedeon Vegyeszet | Process for producing new pyridine derivatives and pharmaceutical copositions comprising same |
US5364943A (en) | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
GB9021056D0 (en) | 1990-09-27 | 1990-11-07 | Pfizer Ltd | Antiarrhythmic agents |
GB9214120D0 (en) | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
AU4718093A (en) | 1992-07-31 | 1994-03-03 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
GB9305672D0 (en) | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
NZ277839A (en) * | 1993-12-29 | 1998-01-26 | Merck Sharp & Dohme | Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
DK0764163T3 (da) | 1994-06-06 | 2002-02-04 | Warner Lambert Co | Tachykinin (NK1) receptor-antagonister |
US6294537B1 (en) | 1995-03-17 | 2001-09-25 | Sanofi-Synthelabo | Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools |
DE69628484T2 (de) * | 1995-03-24 | 2004-05-19 | Takeda Chemical Industries, Ltd. | Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
CN1168719C (zh) | 1996-03-29 | 2004-09-29 | 辉瑞大药厂 | 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途 |
AU4885097A (en) | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
PL350427A1 (en) * | 1999-02-24 | 2002-12-16 | Hoffmann La Roche | Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
DK1103545T3 (da) * | 1999-11-29 | 2004-03-15 | Hoffmann La Roche | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
-
2000
- 2000-02-15 PT PT03026298T patent/PT1394150E/pt unknown
- 2000-02-15 SE SE00102260T patent/SE1035115T5/xx unknown
- 2000-02-15 ES ES03026298T patent/ES2359235T3/es not_active Expired - Lifetime
- 2000-02-15 EP EP03026298A patent/EP1394150B1/en not_active Expired - Lifetime
- 2000-02-15 SI SI200030506T patent/SI1035115T1/xx unknown
- 2000-02-15 AT AT00102260T patent/ATE277905T1/de active
- 2000-02-15 AT AT03026298T patent/ATE496032T1/de active
- 2000-02-15 PT PT00102260T patent/PT1035115E/pt unknown
- 2000-02-15 ES ES00102260T patent/ES2226622T3/es not_active Expired - Lifetime
- 2000-02-15 DE DE60045564T patent/DE60045564D1/de not_active Expired - Lifetime
- 2000-02-15 DK DK03026298.4T patent/DK1394150T3/da active
- 2000-02-15 EP EP00102260A patent/EP1035115B1/en not_active Expired - Lifetime
- 2000-02-15 DK DK00102260T patent/DK1035115T3/da active
- 2000-02-15 DE DE60014216T patent/DE60014216T2/de not_active Expired - Lifetime
- 2000-02-18 PE PE2000000125A patent/PE20001467A1/es not_active IP Right Cessation
- 2000-02-18 GB GB0003908A patent/GB2347422A/en not_active Withdrawn
- 2000-02-18 NZ NZ502948A patent/NZ502948A/en not_active IP Right Cessation
- 2000-02-21 GE GEAP20005227A patent/GEP20022676B/en unknown
- 2000-02-21 CZ CZ20000609A patent/CZ300596B6/cs not_active IP Right Cessation
- 2000-02-21 HU HU0000748A patent/HU227629B1/hu unknown
- 2000-02-21 IL IL134654A patent/IL134654A/en active Protection Beyond IP Right Term
- 2000-02-22 RS YUP-95/00A patent/RS50194B/sr unknown
- 2000-02-22 PA PA20008491101A patent/PA8491101A1/es unknown
- 2000-02-22 UA UA2000021039A patent/UA71547C2/uk unknown
- 2000-02-22 DE DE10008042A patent/DE10008042A1/de not_active Withdrawn
- 2000-02-22 JO JO200014A patent/JO2294B1/en active
- 2000-02-22 US US09/507,456 patent/US6297375B1/en not_active Expired - Lifetime
- 2000-02-22 GT GT200000017A patent/GT200000017A/es unknown
- 2000-02-22 EG EG20000206A patent/EG23817A/xx active
- 2000-02-22 MY MYPI20000648A patent/MY123648A/en unknown
- 2000-02-22 MY MYPI20044751A patent/MY147451A/en unknown
- 2000-02-22 RS RS20080562A patent/RS53869B1/en unknown
- 2000-02-22 FR FR0002170A patent/FR2790473B1/fr not_active Expired - Fee Related
- 2000-02-22 TN TNTNSN00032A patent/TNSN00032A1/fr unknown
- 2000-02-22 RS RSP-2008/0562A patent/RS20080562A/sr unknown
- 2000-02-22 ME MEP-2009-57A patent/ME00593B/me unknown
- 2000-02-22 SK SK235-2000A patent/SK287911B6/sk not_active IP Right Cessation
- 2000-02-22 AR ARP000100737A patent/AR029614A1/es active IP Right Grant
- 2000-02-22 SK SK5052-2008A patent/SK287912B6/sk not_active IP Right Cessation
- 2000-02-22 IS IS5381A patent/IS2116B/is unknown
- 2000-02-23 MA MA25913A patent/MA26722A1/fr unknown
- 2000-02-23 SG SG200001033A patent/SG91856A1/en unknown
- 2000-02-23 EA EA200000155A patent/EA003673B1/ru active Protection Beyond IP Right Term
- 2000-02-23 KR KR10-2000-0008674A patent/KR100384904B1/ko active Protection Beyond IP Right Term
- 2000-02-23 BR BRPI0000908A patent/BRPI0000908B8/pt not_active IP Right Cessation
- 2000-02-23 SV SV2000000024A patent/SV2002000024A/es active IP Right Grant
- 2000-02-23 CN CNB001024019A patent/CN1142144C/zh not_active Expired - Lifetime
- 2000-02-23 NO NO20000885A patent/NO315554B1/no not_active IP Right Cessation
- 2000-02-23 ZA ZA200000894A patent/ZA200000894B/xx unknown
- 2000-02-23 CA CA2299139A patent/CA2299139C/en not_active Expired - Lifetime
- 2000-02-23 IT IT2000MI000328A patent/IT1320763B1/it active
- 2000-02-23 ES ES200000418A patent/ES2171109B2/es not_active Expired - Fee Related
- 2000-02-23 HR HR20000097A patent/HRP20000097B1/xx not_active IP Right Cessation
- 2000-02-24 BG BG104187A patent/BG64554B1/bg unknown
- 2000-02-24 JP JP2000047003A patent/JP3399900B2/ja not_active Expired - Lifetime
- 2000-02-24 TR TR2000/00520A patent/TR200000520A3/tr unknown
- 2000-02-24 OA OA1200000052A patent/OA11680A/fr unknown
- 2000-02-24 AU AU19468/00A patent/AU767048B2/en active Active
- 2000-02-24 PL PL338598A patent/PL217311B1/pl unknown
- 2000-02-25 TW TW089103387A patent/TWI288746B/zh not_active IP Right Cessation
-
2001
- 2001-03-12 HK HK01101744A patent/HK1031223A1/xx unknown
- 2001-07-10 US US09/901,982 patent/US6479483B2/en not_active Expired - Lifetime
-
2007
- 2007-09-24 AR ARP070104196A patent/AR062949A2/es active IP Right Grant
-
2008
- 2008-06-27 HR HRP20080306AA patent/HRP20080306B1/hr not_active IP Right Cessation
-
2009
- 2009-12-10 UY UY0001032314A patent/UY32314A/es not_active Application Discontinuation
-
2011
- 2011-02-10 CY CY20111100162T patent/CY1111317T1/el unknown
-
2015
- 2015-06-17 LU LU92745C patent/LU92745I2/xx unknown
- 2015-07-08 FR FR15C0049C patent/FR15C0049I2/fr active Active
- 2015-08-28 NL NL300758C patent/NL300758I1/nl unknown
- 2015-10-21 LT LTPA2015036C patent/LTC1035115I2/lt unknown
- 2015-10-29 CY CY2015042C patent/CY2015042I1/el unknown
- 2015-10-29 BE BE2015C057C patent/BE2015C057I2/fr unknown
- 2015-10-29 CY CY2015041C patent/CY2015041I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG64554B1 (bg) | 4-фенил-пиридинови производни, метод за получаването им и тяхното използване | |
JP4068305B2 (ja) | 3−フェニルピリジン誘導体、およびそのnk−1受容体拮抗薬としての用途 | |
JP4070957B2 (ja) | フェニルおよびピリジニル誘導体 | |
JP2004504400A (ja) | ニューロキニン1受容体アンタゴニストとしての4−フェニル−ピリジン誘導体 | |
MXPA00001849A (en) | 4-phenylpyridine derivatives and their use as nk-1 receptor antagonists | |
MXPA01008511A (es) | Derivados de 3-fenilpiridina y su uso como antagonistas del receptor de la neuroquinina (nk-1) |